

# Recommended Pneumococcal Immunisation Doses - Feb 2006

## Very high-risk (funded programme) and high-risk (not funded)

Age at start	Recommended pneumococcal immunisation course
6 weeks to 6 months	<b>4 doses PCV7</b> given with routine immunisations at: 6 weeks, 3, 5 and 15 months ( <i>or doses #1, #2 &amp; #3 at least 6-8 weeks apart and #4 at age 15 months</i> ) followed by: <b>2 doses of 23PPV</b> given at: 2 years and 4-5 years of age
7-11 months	<b>3 doses of PCV7</b> given: dose #1 & #2 at least 6-8 weeks apart and #3 at 15 months followed by: <b>2 doses of 23PPV</b> given at: 2 years and 4-5 years of age
12-59 months	<b>2 doses of PCV7</b> given: #1 & #2 at least 6-8 weeks apart followed 6-8 weeks later by: <b>2 doses of 23PPV</b> given: 3-5 years apart (Ideally at 2 years and 4-5 years of age)
5-9 years	<b>1 dose of PCV7</b> followed 6-8 weeks later by: <b>1 dose of 23PPV</b>
10-16 years <sup>1</sup>	<b>1 dose of 23PPV</b>
16 years and older <sup>2</sup>	<b>1 dose of 23PPV</b>

Booster dose of 23PPV 5 yearly - for asplenic patients only

### Footnote:

1. Some paediatricians may recommend one dose of PCV7 and one dose of 23PPV
2. For HIV infected people some specialists may recommend one dose of PCV7 and one dose of 23PPV

## Additional at-risk population groups Recommended BUT NOT FUNDED

Age at start	Recommended pneumococcal immunisation course
6 weeks to 6 months	<b>4 doses PCV7</b> with routine immunisations at: 6 weeks, 3, 5 and 15 months ( <i>or doses #1, #2 &amp; #3 at least 6-8 weeks apart and #4 at age 12-15 months</i> )
7 - 11 months	<b>3 doses of PCV7</b> doses #1 & #2 at least 6-8 weeks apart and dose #3 at age 15 months
12-23 months	<b>2 doses of PCV7</b> dose #1 & #2 given 6-8 weeks apart
24 - 59 months	<b>1 dose of PCV7</b>
Adults over 65 years	<b>1 dose of 23PPV</b>

Key: PCV7-Prevenar® 23PPV-Pneumovax®23

GET THE FACTS ON IMMUNISATION

**0 8 0 0 I M M U N E**  
4 6 6 8 6 3

[www.immune.org.nz](http://www.immune.org.nz)

For detailed vaccine prescribing information refer to the data sheet via [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or the Immunisation Handbook 2006.

# At-risk Groups Recommended for Pneumococcal Immunisation

## Very high-risk individuals (funded)

1. All ages pre or post splenectomy
2. Children (0–16 years) with functional asplenia
3. Children under 5 years of age with the following high-risk conditions
  - On immunosuppressive therapy or radiation therapy
  - Primary immune deficiencies
  - HIV
  - Renal failure or nephrotic syndrome
  - Organ transplants
  - Cochlear implants or intracranial shunts
  - Chronic CSF leaks
  - On corticosteroid therapy for more than 2 weeks, at daily prednisone dose of  $\geq 2$  mg/kg or a total dose  $\geq 20$ mg.

## High-risk individuals (not-funded)

1. All ages over 5 years with the following very high risk conditions:  
on immunosuppressive therapy, primary immune deficiencies, HIV, renal failure or nephrotic syndrome, organ transplants, cochlear implants or intracranial shunts, chronic CSF leaks, on long term corticosteroid therapy
2. Children under 5 with other high risk conditions:  
Pre-term infants born under 28 weeks gestation  
Pre-term infants with chronic lung disease discharged home on oxygen  
Cardiac disease with cyanosis or failure  
Bronchiectasis  
Insulin dependent diabetes  
Down syndrome.
3. Children over 5 and adults with other risk conditions:  
Other Immune compromised conditions eg myeloma, Hodgkin's disease  
Chronic illness eg diabetes, alcoholism, cardiac, renal or pulmonary disease  
Down Syndrome  
Previous pneumococcal invasive disease

## Additional at-risk population groups (not funded)

1. All healthy children < 5 years old  
Particularly Maori and Pacific children and all children attending early childhood services
2. All adults  $\geq 65$  years of age



For detailed vaccine prescribing information refer to the data sheet via [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or the Immunisation Handbook 2006.